Linked Data API

Show Search Form

Search Results

947566
star this property registered interest false remove filter
star this property date less than 2018-07-24more like thismore than 2018-07-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Liothyronine remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of whether the advice provided by PresQIPP to Clinical Commissioning Groups is consistent with national guidelines on the prescription of Liothryonine (T3) to NHS patients. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL9848 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-07-26more like thismore than 2018-07-26
star this property answer text <p>We have not made any assessment on the accuracy and advice provided by PrescQIPP. Nor have we made any assessment on whether the advice provided by PrescQIPP to clinical commissioning groups (CCGs) is consistent with national guidelines on the prescription of liothyronine to National Health Service patients. We can confirm that we have not received any assurances from PrescQIPP on whether or not it has taken patient stakeholder views into account as it is the responsibility of CCGs to seek any such assurances.</p><p>PrescQIPP is an independent social enterprise and it is for CCGs to decide whether and how they take that guidance into account when making decisions. However, NHS England expects CCGs to have due regard to the guidance <em>Items which should not routinely be prescribed in primary care: Guidance for CCGs,</em> published in November 2017 by NHS England and NHS Clinical Commissioners when considering the prescribing of liothyronine. A copy of the guidance is attached.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL9847 more like this
HL9849 more like this
star this property question first answered
less than 2018-07-26T12:46:36.713Zmore like thismore than 2018-07-26T12:46:36.713Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
star this property file name items-which-should-not-be-routinely-precscribed-in-pc-ccg-guidance.pdf more like this
star this property title Items which should not routinely be prescribed more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
931632
star this property registered interest false remove filter
star this property date less than 2018-06-26more like thismore than 2018-06-26
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Liothyronine remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what action they propose to ensure that the Brighton and Sussex University Hospitals NHS Trust withdraws its policy of no longer making Liothyronine (T3) available to NHS patients, contrary to advice issued by NHS England which sets out the circumstances under which Liothyronine (T3) can be prescribed to new patients and continued for existing patients. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL8980 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-07-10more like thismore than 2018-07-10
star this property answer text <p>The national guidelines advise clinical commissioning groups (CCGs) that local decisions should be made regarding arrangements for the on-going prescribing of liothyronine, taking into account the local needs of the population. While CCGs are expected to have regard to national guidance, they are entitled to develop their own local approaches to its implementation. During a debate on 20 June on the Branded Health Service Medicines (Costs) Regulations, I committed to pursuing further with NHS England ways in which they can clarify the guidelines on the prescribing of liothyronine to CCGs, including looking at whether greater clarity on the criteria for appropriate patient usage is merited.</p><p>The prescribing of Liothyronine (T3) was considered by the Sussex and East Surrey Sustainability and Transformation Partnership (STP) clinical board, which covers Brighton and Sussex University Hospitals, and High Weald, Lewes and Havens CCG, following engagement with primary care clinicians and endocrinologists. Based on the evidence presented, the decision not to routinely prescribe Liothyronine (T3) was supported across the STP region. It was, however, recognised that there would be some exceptions to this and that the use of the individual funding request triage process would be an appropriate mechanism to consider these.</p><p><strong> </strong></p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL8981 more like this
HL8982 more like this
HL8983 more like this
star this property question first answered
less than 2018-07-10T15:41:18.18Zmore like thismore than 2018-07-10T15:41:18.18Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
931633
star this property registered interest false remove filter
star this property date less than 2018-06-26more like thismore than 2018-06-26
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Liothyronine remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what action they propose to take to ensure that the High Weald, Lewes and Havens Clinical Commissioning Group withdraws its policy of no longer making Liothyronine (T3) available to NHS patients, contrary to advice issued by NHS England which sets out the circumstances under which Liothyronine (T3) can be prescribed to new patients and continued for existing patients. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL8981 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-07-10more like thismore than 2018-07-10
star this property answer text <p>The national guidelines advise clinical commissioning groups (CCGs) that local decisions should be made regarding arrangements for the on-going prescribing of liothyronine, taking into account the local needs of the population. While CCGs are expected to have regard to national guidance, they are entitled to develop their own local approaches to its implementation. During a debate on 20 June on the Branded Health Service Medicines (Costs) Regulations, I committed to pursuing further with NHS England ways in which they can clarify the guidelines on the prescribing of liothyronine to CCGs, including looking at whether greater clarity on the criteria for appropriate patient usage is merited.</p><p>The prescribing of Liothyronine (T3) was considered by the Sussex and East Surrey Sustainability and Transformation Partnership (STP) clinical board, which covers Brighton and Sussex University Hospitals, and High Weald, Lewes and Havens CCG, following engagement with primary care clinicians and endocrinologists. Based on the evidence presented, the decision not to routinely prescribe Liothyronine (T3) was supported across the STP region. It was, however, recognised that there would be some exceptions to this and that the use of the individual funding request triage process would be an appropriate mechanism to consider these.</p><p><strong> </strong></p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL8980 more like this
HL8982 more like this
HL8983 more like this
star this property question first answered
less than 2018-07-10T15:41:18.227Zmore like thismore than 2018-07-10T15:41:18.227Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
931634
star this property registered interest false remove filter
star this property date less than 2018-06-26more like thismore than 2018-06-26
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Liothyronine remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of the Brighton and Sussex University Hospitals NHS Trust mistakenly stating that the only option for patients wishing to continue Liothyronine (T3) therapy is through the private sector, contrary to advice issued by NHS England which sets out the circumstances under which Liothyronine (T3) can be prescribed to new patients and continued for existing patients. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL8982 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-07-10more like thismore than 2018-07-10
star this property answer text <p>The national guidelines advise clinical commissioning groups (CCGs) that local decisions should be made regarding arrangements for the on-going prescribing of liothyronine, taking into account the local needs of the population. While CCGs are expected to have regard to national guidance, they are entitled to develop their own local approaches to its implementation. During a debate on 20 June on the Branded Health Service Medicines (Costs) Regulations, I committed to pursuing further with NHS England ways in which they can clarify the guidelines on the prescribing of liothyronine to CCGs, including looking at whether greater clarity on the criteria for appropriate patient usage is merited.</p><p>The prescribing of Liothyronine (T3) was considered by the Sussex and East Surrey Sustainability and Transformation Partnership (STP) clinical board, which covers Brighton and Sussex University Hospitals, and High Weald, Lewes and Havens CCG, following engagement with primary care clinicians and endocrinologists. Based on the evidence presented, the decision not to routinely prescribe Liothyronine (T3) was supported across the STP region. It was, however, recognised that there would be some exceptions to this and that the use of the individual funding request triage process would be an appropriate mechanism to consider these.</p><p><strong> </strong></p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL8980 more like this
HL8981 more like this
HL8983 more like this
star this property question first answered
less than 2018-07-10T15:41:18.117Zmore like thismore than 2018-07-10T15:41:18.117Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
931635
star this property registered interest false remove filter
star this property date less than 2018-06-26more like thismore than 2018-06-26
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Liothyronine remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what action they propose to ensure that NHS bodies withdraw policies of no longer making Liothyronine (T3) available to NHS patients, contrary to advice issued by NHS England which sets out the circumstances under which Liothyronine (T3) can be prescribed to new patients and continued for existing patients. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL8983 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-07-10more like thismore than 2018-07-10
star this property answer text <p>The national guidelines advise clinical commissioning groups (CCGs) that local decisions should be made regarding arrangements for the on-going prescribing of liothyronine, taking into account the local needs of the population. While CCGs are expected to have regard to national guidance, they are entitled to develop their own local approaches to its implementation. During a debate on 20 June on the Branded Health Service Medicines (Costs) Regulations, I committed to pursuing further with NHS England ways in which they can clarify the guidelines on the prescribing of liothyronine to CCGs, including looking at whether greater clarity on the criteria for appropriate patient usage is merited.</p><p>The prescribing of Liothyronine (T3) was considered by the Sussex and East Surrey Sustainability and Transformation Partnership (STP) clinical board, which covers Brighton and Sussex University Hospitals, and High Weald, Lewes and Havens CCG, following engagement with primary care clinicians and endocrinologists. Based on the evidence presented, the decision not to routinely prescribe Liothyronine (T3) was supported across the STP region. It was, however, recognised that there would be some exceptions to this and that the use of the individual funding request triage process would be an appropriate mechanism to consider these.</p><p><strong> </strong></p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL8980 more like this
HL8981 more like this
HL8982 more like this
star this property question first answered
less than 2018-07-10T15:41:18.29Zmore like thismore than 2018-07-10T15:41:18.29Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
834485
star this property registered interest false remove filter
star this property date less than 2018-01-31more like thismore than 2018-01-31
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Liothyronine remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether they intend to commission research to evaluate the impact on patients of reduced access to liothyronine (T3) for the treatment of thyroid disease. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL5291 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-02-08more like thismore than 2018-02-08
star this property answer text <p>We understand that whilst it is recognised that some patients on levothyroxine remain symptomatic despite treatment leading to thyroid stimulating hormone levels in the therapeutic range, it is not possible to predict the number as the reasons for this are not fully understood; such patients should be under the care of an endocrinologist. Where clinical commissioning groups decide to implement recommendations in NHS England’s guidance, they are responsible for deciding whether further action is required, such as commissioning research, to monitor uptake and outcomes.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN HL5226 more like this
star this property question first answered
less than 2018-02-08T15:11:48.057Zmore like thismore than 2018-02-08T15:11:48.057Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
833608
star this property registered interest false remove filter
star this property date less than 2018-01-30more like thismore than 2018-01-30
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Liothyronine remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether any Clinical Commissioning Groups refused to allow patients to be prescribed liothyronine (T3) before the consultation on Items which should not be routinely prescribed in primary care: Guidance for CCGs commenced; and if so, why. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL5228 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-02-08more like thismore than 2018-02-08
star this property answer text <p>We understand that the British Thyroid Association (BTA) advises that a small proportion of patients treated with the most commonly used drug, levothyroxine, continue to suffer with symptoms despite adequate biochemical correction. In these circumstances, where levothyroxine has failed and in line with BTA guidance, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of at least three months’ duration of liothyronine.</p><p>NHS England’s recommendations to clinical commissioning groups (CCGs) take account of those of the BTA and are to:</p><p>- Advise CCGs that prescribers in primary care should not initiate liothyronine for any new patient;</p><p> </p><p>- Advise CCGs that individuals currently prescribed liothyronine should be reviewed by a consultant NHS endocrinologist with consideration given to switching to levothyroxine where clinically appropriate; and</p><p> </p><p>- Advise CCGs that a local decision, involving the Area Prescribing Committee (or equivalent) informed by national guidance (e.g. from the National Institute for Health and Care Excellence or the Regional Medicines Optimisation Committee), should be made regarding arrangements for on-going prescribing of liothyronine. This should be for individuals who, in exceptional circumstances, have an on-going need for liothyronine as confirmed by a consultant National Health Service endocrinologist.</p><p>A number of CCGs had already created local policies on the prescribing of liothryronine before the national consultation started in July 2017.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN HL5225 more like this
star this property question first answered
less than 2018-02-08T15:03:07.447Zmore like thismore than 2018-02-08T15:03:07.447Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
1361539
star this property registered interest false remove filter
star this property date less than 2021-10-19more like thismore than 2021-10-19
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Liothyronine remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what steps NHS Clinical Commissioners took to communicate national guidance for the prescribing of liothyronine to local NHS bodies; and whether that guidance says that liothyronine may only be prescribed when recommended by a specialist after treatment using levothyroxine has failed. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL3197 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2021-10-29more like thismore than 2021-10-29
star this property answer text <p>National Health Service clinical commissioners have promoted national guidance through their bulletins with clinical commissioning groups members. National guidance recommends that in circumstances where levothyroxine has failed, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of liothyronine for at least three months duration.</p><p>We have made no assessment on whether liothyronine should be de-classified as a high cost medicine. To date, NHS England NHS Improvement have not conducted any specific assessments on liothyronine following the Competition and Markets Authority ruling. This will be considered as part of any formal review to national guidance.</p> more like this
star this property answering member printed Lord Kamall more like this
star this property grouped question UIN HL3198 more like this
star this property question first answered
less than 2021-10-29T09:52:10.957Zmore like thismore than 2021-10-29T09:52:10.957Z
star this property answering member
4909
star this property label Biography information for Lord Kamall more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
1361540
star this property registered interest false remove filter
star this property date less than 2021-10-19more like thismore than 2021-10-19
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Liothyronine remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of whether liothyronine should be declassified as a high-cost medicine following the Competition and Markets Authority ruling and fine issued to Advanz for artificially inflating the price of thyroid tablets. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL3198 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2021-10-29more like thismore than 2021-10-29
star this property answer text <p>National Health Service clinical commissioners have promoted national guidance through their bulletins with clinical commissioning groups members. National guidance recommends that in circumstances where levothyroxine has failed, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of liothyronine for at least three months duration.</p><p>We have made no assessment on whether liothyronine should be de-classified as a high cost medicine. To date, NHS England NHS Improvement have not conducted any specific assessments on liothyronine following the Competition and Markets Authority ruling. This will be considered as part of any formal review to national guidance.</p> more like this
star this property answering member printed Lord Kamall more like this
star this property grouped question UIN HL3197 more like this
star this property question first answered
less than 2021-10-29T09:52:10.897Zmore like thismore than 2021-10-29T09:52:10.897Z
star this property answering member
4909
star this property label Biography information for Lord Kamall more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
1360890
star this property registered interest false remove filter
star this property date less than 2021-10-18more like thismore than 2021-10-18
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Liothyronine remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government, further to the Written Answer by Lord Bethell on 17 March (HL14040), what assessment they have made as to whether the fall in the price of Liothyronine (T3) is related to increased competition from marketing authorisations granted since 2016. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL3158 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2021-10-22more like thismore than 2021-10-22
star this property answer text <p>We have made no further assessment of the price of Liothyronine relative to increased competition from marketing authorisations or the cost of medicines in other parts of Europe. Further marketing authorisation applications remain at the discretion of pharmaceutical companies.</p> more like this
star this property answering member printed Lord Kamall more like this
star this property grouped question UIN
HL3159 more like this
HL3160 more like this
star this property question first answered
less than 2021-10-22T10:19:03.8Zmore like thismore than 2021-10-22T10:19:03.8Z
star this property answering member
4909
star this property label Biography information for Lord Kamall more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter